Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19464666 | 0.83 | NR1I2 (0.38) | GRM5KDM4EALDH1A1ALOX15HSD17B10 | |
| SCHEMBL19231989 | 0.81 | GPR84 (0.38) | GPR84SLC2A1OPRM1 | |
| SCHEMBL21755168 | 0.79 | OPRM1 (0.38) | GPR84KDM4EALDH1A1ALOX15HSD17B10 | |
| SCHEMBL19232020 | 0.77 | SLC2A1 (0.36) | GPR84SLC2A1OPRM1 | |
| SCHEMBL19231971 | 0.77 | SLC2A1 (0.36) | GPR84SLC2A1OPRM1 | |
| SCHEMBL21755084 | 0.75 | ACACB (0.36) | GPR84ALDH1A1HSD17B10SLC2A1 | |
| SCHEMBL19987490 | 0.75 | SLC2A1 (0.35) | GPR84SLC2A1OPRM1 | |
| SCHEMBL19987523 | 0.75 | NR1I2 (0.39) | GRM5KDM4EALDH1A1ALOX15HSD17B10 | |
| SCHEMBL18661804 | 0.73 | SLC2A1 (0.39) | GPR84SLC2A1NR1I2 | |
| SCHEMBL21730035 | 0.72 | GAA (0.43) | ALDH1A1ALOX15HSD17B10SLC2A1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210244721-A1 | SMALL MOLECULE ENTEROVIRUS INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-08-12 | — | — | US | disclosed |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-10167254-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167254-B2 | IDO inhibitors | IDO1, IDO2, INMT | GPR84 2521/4885GRM5 1674/4885KDM4E 272/4885 |
| US-20210244721-A1 | SMALL MOLECULE ENTEROVIRUS INHIBITORS AND USES THEREOF | AR, KLK3, BRDT | GPR84 74/4885GRM5 277/4885KDM4E 2146/4885 |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | GPR84 1928/4885GRM5 1099/4885KDM4E 375/4885 |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | GPR84 1928/4885GRM5 1099/4885KDM4E 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.